ANI Pharmaceuticals Incのファンダメンタルズは比較的健全です。成長の可能性は高いです。バリュエーションは適正価格と評価されています。 医薬品業界のランキングは3/158位です。機関投資家保有率は非常に高いです。過去1か月間に複数のアナリストが買いと評価し、最高目標株価は108.00とされています。中期的には、株価は下降トレンドと予想されます。過去1か月の株式市場のパフォーマンスは平均的でしたが、同社のファンダメンタルズとテクニカルは堅調です。株価は支持線と抵抗線の間で横ばい推移しており、レンジ相場でのスイングトレードに適しています。
ANI Pharmaceuticals Incのスコア
関連情報
業界内順位
3 / 158
全体ランキング
20 / 4582
業種
医薬品
支持線と抵抗線
会社から関連データがまだ開示されていません。
レーダーチャート
現在
前回値
アナリスト目標株価
9
人のアナリスト予想に基づく
買い
現在の評価
108.000
目標株価
+32.78%
上昇余地
免責事項:アナリストのレーティングおよび目標株価は、情報提供のみを目的としてLSEG Data & Analyticsが提供するものであり、投資助言を構成するものではありません。
ANI Pharmaceuticals Incの注目ポイント
強みリスク
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
企業コードANIP
企業名ANI Pharmaceuticals Inc
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
ウェブサイトhttps://www.anipharmaceuticals.com/
よくある質問
ANI Pharmaceuticals Inc(ANIP)の現在の株価はいくらですか?
ANI Pharmaceuticals Inc(ANIP)の現在の株価は82.850です。
ANI Pharmaceuticals Incのティッカーシンボルは何ですか?
ANI Pharmaceuticals IncのティッカーシンボルはANIPです。
ANI Pharmaceuticals Incの52週高値はいくらですか?
ANI Pharmaceuticals Incの52週高値は99.500です。
ANI Pharmaceuticals Incの52週安値はいくらですか?
ANI Pharmaceuticals Incの52週安値は52.500です。
ANI Pharmaceuticals Incの時価総額はいくらですか?
ANI Pharmaceuticals Incの時価総額は1.86Bです。
ANI Pharmaceuticals Incの純利益はいくらですか?
ANI Pharmaceuticals Incの純利益は-20.15Mです。
ANI Pharmaceuticals Inc (ANIP) の現在の評価は「買い」、「ホールド」、「売り」のどれですか?